Dianthus Therapeutics Beats Q3 2026 Estimates as Revenue Rises 206% to $1.2M

Dianthus Therapeutics (DNTH) beat estimates for the third quarter of 2026 on both revenue and adjusted EPS. Revenue was $1.2 million, up 206% from a year earlier, above the $461 thousand estimate, and adjusted EPS was -$0.81, up 16% from a year earlier, above the -$0.94 estimate.

Q3 2026 scorecard

By our calculation, revenue was $749 thousand above the estimate and adjusted EPS was $0.13 above it. The QoQ column compares with the previous quarter's revenue of $761 thousand and adjusted EPS of -$0.90. The YoY column compares with $396 thousand and -$0.97 in the same quarter a year earlier.

Track record

• EPS record. Adjusted EPS beat the estimate in 4 of the last 8 reports, including this one.
• Revenue record. Revenue beat the estimate in 5 of the last 8 reports.
• Revenue trend. Revenue over the last 5 reports, oldest first: $396 thousand, $284 thousand, $463 thousand, $761 thousand and $1.2 million.

What to watch

• Next-quarter estimates. Consensus calls for EPS of -$1.07 and revenue of $381 thousand next quarter, based on 8 analysts.
• Next report. Dianthus Therapeutics is next expected to report on March 8, 2027.
• Revenue growth. Whether revenue keeps growing from a year earlier after this quarter's 206% increase to $1.2 million.
• Related coverage. See our reports on Titan America, Personalis, Nutrien and Trekor Metals.

Sources: Results are from Dianthus Therapeutics's Nov. 4, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Dianthus Therapeutics's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.